CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-05 | Blum Robert I President & CEO | Gift | −2,000 | 356,108 | ||
| 2025-11-04 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,295 | $10.60 | $24K | 142,905 |
| 2025-11-04 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,295 | $59.55 | $137K | 140,610 |
| 2025-11-04 | Malik Fady Ibraham EVP Research & Development | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −2,295 | 6,600 | ||
| 2025-10-30 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $62.86 | $314K | 358,108 |
| 2025-10-27 | WIERENGA WENDELL Director | Option exercise 10b5-1 | +4,375 | $10.00 | $44K | 36,819 |
| 2025-10-27 | WIERENGA WENDELL Director | Sale 10b5-1 | −4,375 | $58.68 | $257K | 32,444 |
| 2025-10-27 | WIERENGA WENDELL Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −4,375 | 0 | ||
| 2025-10-21 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,105 | $10.60 | $22K | 142,715 |
| 2025-10-21 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,105 | $58.22 | $123K | 140,610 |
| 2025-10-21 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,105 | 1,000 | ||
| 2025-10-16 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $60.03 | $300K | 363,108 |
| 2025-10-15 | WIERENGA WENDELL Director | Grant or award | +99 | $62.80 | $6K | 32,444 |
| 2025-10-15 | Harrington Robert Arthur Director | Grant or award | +199 | $62.80 | $12K | 20,692 |
| 2025-10-15 | HENDERSON JOHN T Director | Grant or award | +338 | $62.80 | $21K | 74,578 |
| 2025-10-15 | Kaye Edward M. MD Director | Grant or award | +199 | $62.80 | $12K | 9,977 |
| 2025-10-15 | Wysenski Nancy Director | Grant or award | +99 | $62.80 | $6K | 30,873 |
| 2025-10-07 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,610 |
| 2025-10-07 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $60.56 | $121K | 140,610 |
| 2025-10-07 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 3,105 |
Page 16 of 22 · 429 trades